OMIC-CARD: Metabolomics, Genomics and Nutrition for Cardiovascular Disease Precision Medicine

Sponsor
Fundacion Miguel Servet (Other)
Overall Status
Recruiting
CT.gov ID
NCT05706519
Collaborator
(none)
1,200
6
16.4
200
12.2

Study Details

Study Description

Brief Summary

The objective of this project is to validate, through high-throughput advanced metabolomics techniques, the nutritional assessment tools to be used in the IMPaCT cohort. At the same time, the ability of metabolomics fingerprints of nutritional patterns to discriminate between patients with and without major cardiovascular disease will be identified. Finally, the modification of these predictions will be evaluated based on the genetic profiles. The main hypothesis holds that the integration of metabolomics, genomic and nutritional information will serve to personalize the approach to cardiovascular disease, both in prevention and treatment, and that these tools, in turn, will be valid enough to be applied systematically and efficiently in the IMPaCT cohort.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    In two independent samples, one of 600 subjects free of cardiovascular disease (control group) and the other of 600 subjects with a history of ischemic heart disease (established heart disease group) eating habits will be evaluated using Food Frequency Questionnaire, based on those repeatedly used in epidemiological studies carried out in Spain, as well as other nutritional evaluation tools. Each participant will undergo a complete plasma metabolomics profile with identification of > 300 metabolites and a complete genome-wide association analysis. Artificial intelligence models and elastic net regression self-learning algorithms will be applied to select the metabolomics fingerprint of eating patterns.

    The objectives are:
    • To assess whether the relationship between diet and metabolic footprint is similar in those with established Cardio Vascular Disease or not. This will allow evaluating the usefulness of metabolic fingerprint to monitor the metabolic response to diet in patients with Cardio Vascular Disease and thus help to individualize their pharmacological and non-pharmacological treatment (diet and lifestyle)

    • If there are sociodemographic characteristics - including the gender perspective-, clinical or genetic characteristics that help identify people who present a greater metabolic response to diet both in people without and in people with Cardio Vascular Disease.

    • If the possible limitations of the metabolic footprint of different dietary patterns are reduced by using different tools for the collection of nutritional information. Self -completed Food Frequency Questionnaire a, Food Frequency Questionnaire b completed with telephone interviewer, brief assessment tools, and 4 dietary records of 3 days each distributed throughout the year will be used.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    1200 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Cross-Sectional
    Official Title:
    Metabolomics, Genomics and Nutrition for Cardiovascular Disease Precision Medicine
    Actual Study Start Date :
    Dec 19, 2022
    Anticipated Primary Completion Date :
    May 1, 2024
    Anticipated Study Completion Date :
    May 1, 2024

    Arms and Interventions

    Arm Intervention/Treatment
    Control Group

    Six hundred volunteers. This group has to be without any type of cardiovascular Disease.

    Case Group

    Six hundred volunteers. In this group, participants must present a diagnosis of ischemic heart disease at least 1 year but less than 5 years from recruitment

    Outcome Measures

    Primary Outcome Measures

    1. Metabolomics [Baseline]

      Human plasma and serum will be analysed to obtain chemical information of the different families of metabolites.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    50 Years to 79 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Age between 50 - 79 years old

    • Living in Spain for more than 2 years

    • Fluent in Spanish

    • Ability for answer all the study questionaries'

    • Ability to validly grant informed consent

    • Ability to move on one's own

    • Not under palliative care due to serious illness, institutionalized population will not be recruited

    • Not planning any change of address to another autonomous community within a year.

    • Receive health care in National Health System. Officials or self-employed workers with health coverage exclusively in "Mutuas" that do not allow telematics access to health data will be excluded.

    Exclusion Criteria:
    • Chronic alcoholism or regular alcohol consumption > 80 g/d

    • BMI >40 kg/m²

    • Participation in a clinical trial conducted with drugs or use of any drug in experimental status during the year prior to inclusion

    • Patient with cancer treatment two years before

    • Patient with history of gastrectomy or intestinal resection. Patients with acute infection or inflammatory process (e.g. Pneumonia), may be included in the study three months after the infectious process.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 ibs.GRANADA Granada Andalucia Spain 18012
    2 Instituto de Investigación Sanitaria Vitoria Araba Spain 01009
    3 Universidad de Cantabria Santander Cantabria Spain 39011
    4 Institut D' Investigació Sanitària Illes Balears Palma De Mallorca Illes Balears Spain 07122
    5 Servicio Navarro de Salud Osasunbidea Pamplona Navarra Spain 31006
    6 UAM Madrid Spain 28029

    Sponsors and Collaborators

    • Fundacion Miguel Servet

    Investigators

    • Principal Investigator: Pilar Buil- Cosiales, Doctor, Servicio Navarro de Salud - Osasunbidea

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Fundacion Miguel Servet
    ClinicalTrials.gov Identifier:
    NCT05706519
    Other Study ID Numbers:
    • PMP21/00125
    First Posted:
    Jan 31, 2023
    Last Update Posted:
    Feb 3, 2023
    Last Verified:
    Jan 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Fundacion Miguel Servet
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 3, 2023